Company
Novavax, Inc.
NASDAQ:NVAX
Novavax is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology.
32 stories
Novavax slumps after halving its sales forecast amid global supply glut and low vaccine demand
The US biotech company now expects total revenues for 2022 to be in the range of US$2bn-US$2.3bn, down from its prior forecast of US$4bn-US$5bn
Novavax Covid-19 vaccine recommended for US approval by FDA advisory panel
If approved by the FDA, the Novavax shot would become the first protein-based Covid-19 vaccine available in the US
Archive
US stock flirt with new record highs as investors shrug off Omicron concern
US stock indexes grew after figures showed that consumer-spending growth cooled last month
Novavax says COVID-19 vaccine 90% effective, also tested in combination with influenza jab
The UK has booked 60mln doses of the jab, though Novavax has yet to file documents for approval
Novavax expands late-stage UK trial for COVID-19 vaccine candidate to 15,000 volunteers
So far the firm has enrolled 5,500 participants to date and expects to complete the recruitment by the end of November
Novavax to present on COVID-19 vaccine candidate this week
The company is attending the 2020 World Vaccine Congress Washington scheduled for this week
Novavax to start late-stage trials for COVID-19 vaccine in UK
The US firm will enrol up to 10,000 participants aged 18-84 over the next six weeks
Archive
The week in coronavirus: Westminster wants people back to work, low-income people paid to quarantine, more job cuts from Gatwick Airport and others…
A look at the week's major news regarding the pandemic
Novavax expects to submit COVID-19 vaccine before US authorities in December
Data from the second phase of clinical trials is expected in the fourth quarter of 2020
Novavax to provide 60mln COVID-19 vaccine doses to UK government
AstraZeneca also announced plans to make 400mln doses of a COVID-19 vaccine for Latin American countries in early 2021
Novavax to start human trials for Covid-19 vaccine candidate in Australia
Results of the first portion of trials are expected for July
Novavax shares surge following positive Phase 2 trial of flu vaccine
The clinical-stage biotech plans to meet with the FDA in the first half of the year to discuss the Phase 2 clinical trial results
Shares of Novavax slide after company's public offering was priced lower than previous stock close
The stock was priced 21% lower than previous closing price
Novavax shares leap pre-market after a study of its new flu vaccine approach showed stronger results than standard vaccine
Novavax said its NanoFlu recombinant vaccine was 47% to 64% more effective against different strains of H3N2 than the standard flu vaccine
Novavax soars on positive phase III trial of its RSV vaccine
Those who were given the RSV F vaccine had a 52% reduction in recent respiratory syncytial virus (RSV) infection
Archive
Oracle shares fall despite reiterated recommendation
Tech group Oracle Corp was reiterated as Neutral with a share price target of $41 by brokers at Wedbush on Friday but Novavax shares endure a drubbing
Novavax shares collapse after failed Phase III trial
The company’s respiratory syncytial virus vaccine did meet the primary or secondary objectives of the trial
US shares end down on oil, banks, but resilient on week
US stocks ended Friday lower after oil prices and a spat involving Deutsche Bank saw investors flee energy and banking stocks – but resilient on the week
Trending: American Apparel, Twitter, McDonald’s, Naked Brands, Oncomed Pharma & more
Clothing retailer American Apparel was given the green light to exit bankruptcy, and now a group of hedge funds are set to takeover the group.
Novavax to offer $200mln in convertible senior notes due 2023
The proceeds will be used to advance its clinical-stage vaccine candidates.